Subscribe FREE to: Magazine | Newsletter | Linked In | Twitter Facebook


ODT Magazine


Search  


Latest News



ODT Magazine - RODMAN PUBLISHING CORP. Get it on Google Play


Sanuwave Adds to Board




Alpharetta, Ga.-based Sanuwave Health Inc. has named Alan L. Rubino to its board of directors. Rubino has more than 30 years of experience at every level of the biopharmaceutical industry, including positions focused on sales and marketing and U.S. Securities and Exchange Commission (SEC) matters. With this appointment, the company’s board has four members.

“We are delighted to welcome Alan to our board of directors,” said Kevin A. Richardson, chairman of the board of directors of Sanuwave. “Throughout his career, Rubino has developed a strong network of industry experts including medical device distributors. His industry knowledge and strong relationships with companies that are addressing chronic diabetes issues will be of great value to Sanuwave.”

Rubino has served as president and CEO of Emisphere Technologies Inc. since September 2012. Previously, he served as president and CEO of New American Therapeutics Inc., president and CEO of Akrimax Pharmaceuticals LLC, and president and chief operating officer of Pharmos Corporation. Rubino has also worked at Hoffmann-La Roche Inc. where he was a member of the U.S. Executive and Operating Committees and an SEC corporate officer. During his Roche tenure, he held executive positions in marketing, sales, business operations, supply chain and human resource management, and was assigned executive committee roles in marketing, project management, and globalization. He has held senior executive positions at PDI Inc. and Cardinal Health. He holds a BA in economics from Rutgers University with a minor in biology/chemistry and completed post-graduate educational programs at the University of Lausanne, Switzerland, and Harvard Business School. Rubino serves on the boards of Aastrom Biosciences Inc. and Genisphere LLC and is also on the Rutgers University Business School board of advisors.

“Sanuwave represents a compelling growth opportunity with the dermaPACE Phase III clinical trial underway in the United States and the on-going use of the dermaPACE and orthoPACE devices outside the United States,” said Rubino. “I look forward to working with the management team to expand the international distribution of their medical devices and to develop value-enhancing strategies to compete in multiple large market opportunities.”

Sanuwave develops shock wave technology company for non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. The company’s PACE technology is applied to wound healing (dermaPACE), spine (orthoPACE), cosmetic and cardiac conditions.




Copyright © 2014 Rodman Media. All Rights Reserved. All rights reserved. Use of this constitutes acceptance of our Privacy Policy
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.